JP2008535475A - Ｑ３ｓｐａｒｃ欠失変異体及びその使用 - Google Patents

Ｑ３ｓｐａｒｃ欠失変異体及びその使用 Download PDF

Info

Publication number
JP2008535475A
JP2008535475A JP2007556317A JP2007556317A JP2008535475A JP 2008535475 A JP2008535475 A JP 2008535475A JP 2007556317 A JP2007556317 A JP 2007556317A JP 2007556317 A JP2007556317 A JP 2007556317A JP 2008535475 A JP2008535475 A JP 2008535475A
Authority
JP
Japan
Prior art keywords
sparc
antibody
polypeptide
composition
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007556317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535475A5 (enExample
Inventor
チェウ、ヴオン
デサイ、ネイル、ピー．
スーン−ショーン、パトリック
Original Assignee
アブラクシス バイオサイエンス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス、インコーポレイテッド filed Critical アブラクシス バイオサイエンス、インコーポレイテッド
Publication of JP2008535475A publication Critical patent/JP2008535475A/ja
Publication of JP2008535475A5 publication Critical patent/JP2008535475A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2007556317A 2005-02-18 2006-02-17 Ｑ３ｓｐａｒｃ欠失変異体及びその使用 Pending JP2008535475A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65426105P 2005-02-18 2005-02-18
PCT/US2006/005615 WO2006112930A2 (en) 2005-02-18 2006-02-17 Q3 sparc deletion mutant and uses thereof

Publications (2)

Publication Number Publication Date
JP2008535475A true JP2008535475A (ja) 2008-09-04
JP2008535475A5 JP2008535475A5 (enExample) 2009-04-02

Family

ID=37000156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007556317A Pending JP2008535475A (ja) 2005-02-18 2006-02-17 Ｑ３ｓｐａｒｃ欠失変異体及びその使用

Country Status (7)

Country Link
US (3) US7332568B2 (enExample)
EP (1) EP1869077A2 (enExample)
JP (1) JP2008535475A (enExample)
CN (1) CN101160321A (enExample)
AU (1) AU2006237613A1 (enExample)
CA (1) CA2598510C (enExample)
WO (1) WO2006112930A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
CA2598239C (en) * 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
AU2006284657B2 (en) * 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP5590882B2 (ja) * 2006-06-26 2014-09-17 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 化学療法増感剤としてのシステインに富む酸性分泌タンパク質（ｓｐａｒｃ）
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2015081096A2 (en) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
ES2389828T3 (es) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
WO2009111375A2 (en) * 2008-03-01 2009-09-11 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
US20110152169A1 (en) * 2008-04-14 2011-06-23 Kouros Motamed Sparc anti-inflammatory activity and uses thereof
MX2011005968A (es) * 2008-12-05 2011-07-19 Abraxis Bioscience Llc Enfoque de enfermedad mediada por peptido enlazado a albumina.
CN104174025B (zh) 2008-12-05 2017-01-11 阿布拉西斯生物科学有限责任公司 Sparc结合肽及其应用
AU2013228006B2 (en) * 2008-12-05 2016-05-12 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
US20120087910A1 (en) * 2009-03-11 2012-04-12 Abraxis Bioscience, Llc Sparc angiogenic domain and methods of use
EP2478362B1 (en) * 2009-09-18 2016-05-11 Abraxis BioScience, LLC Use of the sparc microenvironment signature in the treatment of cancer
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
CN103221062A (zh) * 2010-06-03 2013-07-24 阿布拉西斯生物科学有限责任公司 外周血sparc 结合抗体及其用途
WO2011153485A2 (en) 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Use of the sparc microenvironment signature in the treatment of cancer
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090544A2 (en) * 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
JP2003504044A (ja) * 1999-07-07 2003-02-04 インサイト・ゲノミックス・インコーポレイテッド アテローム性動脈硬化に関連する遺伝子
US20040118579A1 (en) * 2002-12-19 2004-06-24 3M Innovative Properties Company Flexible heat sink
WO2004064785A2 (en) * 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
WO2004091383A2 (en) * 2003-04-01 2004-10-28 Genzyme Corporation Breast endothelial cell expression patterns
JP2007537460A (ja) * 2004-05-14 2007-12-20 アブラクシス バイオサイエンス、インコーポレイテッド アルブミン結合蛋白質を標的として用いる治療法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5128247A (en) 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5130423A (en) 1990-07-13 1992-07-14 Microprobe Corporation Non-corrosive compositions and methods useful for the extraction of nucleic acids
IL108497A0 (en) 1993-02-01 1994-05-30 Seq Ltd Methods and apparatus for dna sequencing
CA2161095A1 (en) 1993-04-20 1994-10-27 Solis Therapeutics, Inc. Methods and materials for treatment of individuals infected with intracellular infectious agents
US5945515A (en) 1995-07-31 1999-08-31 Chomczynski; Piotr Product and process for isolating DNA, RNA and proteins
JP2001522226A (ja) 1997-01-31 2001-11-13 リサーチ コーポレイション テクノロジーズ インコーポレイテッド セミ−同種異系細胞での癌の免疫療法
DE19740571C1 (de) 1997-09-15 1999-03-18 Gsf Forschungszentrum Umwelt Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität
US6316193B1 (en) 1998-10-06 2001-11-13 Origene Technologies, Inc. Rapid-screen cDNA library panels
US20040018188A9 (en) * 1999-01-20 2004-01-29 Incyte Genomics, Inc. Sparc-related proteins
US6387664B1 (en) 1999-02-26 2002-05-14 Secretary Of Agency Of Industrial Science And Technology Sparc fusion protein and method for producing the same
EP1217891B1 (en) 1999-09-24 2009-12-16 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
AU2001259131A1 (en) 2000-04-25 2001-11-07 Dna Sciences, Inc. Detection of nucleotide sequence variations via the proofreading activity of polymerases
AU2003281325A1 (en) 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003504044A (ja) * 1999-07-07 2003-02-04 インサイト・ゲノミックス・インコーポレイテッド アテローム性動脈硬化に関連する遺伝子
WO2002090544A2 (en) * 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
US20040118579A1 (en) * 2002-12-19 2004-06-24 3M Innovative Properties Company Flexible heat sink
WO2004064785A2 (en) * 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
WO2004091383A2 (en) * 2003-04-01 2004-10-28 Genzyme Corporation Breast endothelial cell expression patterns
JP2007537460A (ja) * 2004-05-14 2007-12-20 アブラクシス バイオサイエンス、インコーポレイテッド アルブミン結合蛋白質を標的として用いる治療法

Also Published As

Publication number Publication date
US20060199248A1 (en) 2006-09-07
US7332568B2 (en) 2008-02-19
CA2598510A1 (en) 2006-10-26
US20080182258A1 (en) 2008-07-31
CA2598510C (en) 2011-12-20
WO2006112930A2 (en) 2006-10-26
CN101160321A (zh) 2008-04-09
WO2006112930A3 (en) 2007-04-05
AU2006237613A1 (en) 2006-10-26
EP1869077A2 (en) 2007-12-26
US20110009337A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
US20110009337A1 (en) Q3 sparc deletion mutant and uses thereof
JP5580329B2 (ja) Ｓｐａｒｃ結合ペプチド及びその使用
US10118961B2 (en) Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV
JP5496220B2 (ja) アルブミン結合ペプチド介在性の疾患標的化
AU2006304418B2 (en) Inhibition of placenta growth factor (PIGF) mediated metastasis and/or angiogenesis
CN101044242B (zh) 肿瘤特异性抗体
CN101925612A (zh) 针对癌相关的nfkbib变体的表位的抗体及其用途
CN107667120A (zh) 抗muc16抗体及其应用
KR20020073181A (ko) Ｌｉｖ-1 관련 단백질, 이를 코딩하는 폴리뉴클레오티드및 암의 치료를 위한 그의 용도
JP2012508025A (ja) Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法
JP2010077026A (ja) がん関連マクロファージを標的とした固形がん治療剤
US20050260132A1 (en) Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
JP2022515131A (ja) リン酸化ダイサー抗体およびその使用方法
US20130230899A1 (en) Therapeutic agent for arteriosclerosis or arteriosclerotic disease, and diagnostic agent for arteriosclerosis or arteriosclerotic disease
TW201711702A (zh) 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
CN120590505A (zh) 一种重组补体蛋白及在制备抗白血病药物中的应用
AU2015201325B2 (en) Methods for diagnosing and treating cancers
JP5822407B2 (ja) 軟骨・骨破壊抑制剤
JPWO2014142356A1 (ja) 強皮症治療剤
JP2003169683A (ja) 新規脱共役蛋白質ｍｔ００２９
HK1151973A (en) Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090213

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20101013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120424